The plant can reach an annual capacity of 300 crore tablets and 90 crore capsules
The inspection concluded with one minor observation in Form 483
The positive CHMP opinion is supported by results from the Phase III QUASAR trial
This partnership strengthens LMS as a leading CDMO supplier of peptide materials for both innovator and generic markets
This is the first approval of a prescription transdermal dosage Form in the European markets from this facility
The cobas Mass Spec solution Ionify reagent portfolio now covers therapeutic drug monitoring for immunosuppressants and antibiotics
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
This strategic investment aims to bolster the company's position as a global leader in Vitamin D3 manufacturing
Subscribe To Our Newsletter & Stay Updated